History and physical examination Between Days Routine tests. 18 and 21 Routine urine test (cycles 2, 4 and 6) Day 22 next cycle (Day 1 of next Cycle) Cycle 2 (for patients who will have interval cytoreductive surgery) Day What you do Pre-chemotherapy medications by IV or mouth to prevent allergic reactions Go to your doctor’s office or infusion center for treatment. Receive paclitaxel and carboplatin into your vein. You will be there for Day 1 approximately 2 hours. If you are receiving bevacizumab: pressure measurement Receive bevacizumab into your vein over 30-90 minutes Get routine tests. If you are in Regimen II, receive IV paclitaxel over 1 hour. Day 8 If you are receiving bevacizumab: Blood pressure measurement Between Days Get your kidney health checked if it has not been done recently (10/22/2012) 8 and 10 Get a perfusion CT scan (Cycle 2) Get routine blood tests. If you are in Regimen II, receive IV paclitaxel over 1 hour. Day 15 If you are receiving bevacizumab: Blood pressure measurement History and physical examination Between Days Routine blood tests. 18 and 21 Routine urine test Day 22 Begin next cycle (Day 1 of next Cycle) Cycles 3 and 4 (for patients who will have interval cytoreductive surgery) Day What you do Pre-chemotherapy medications by IV or mouth to prevent allergic reactions Go to your doctor’s office or infusion center for treatment. Day 1 Receive paclitaxel and carboplatin into your vein. You will be there for approximately 2 hours. Examination of incision if partially open since abdominal surgery (cycle 4) Get routine blood tests. (for primary surgery patients only) Day 8 Examination of incision if partially open since abdominal surgery (cycle 4) If you are in Regimen II, receive IV paclitaxel over 1 hour. Get routine tests. Day 15 Examination of incision if still partially open since abdominal surgery (cycle 4) If you are in Regimen II, receive IV paclitaxel over 1 hour. Between Days CT or MRI scan (Cycle 3 and Cycle 6) 15 and 21 Have interval cytoreductive surgery (cycle 3)
Between Days 18 and 21 History and physical examination Routine tests. Routine urine test (cycles 2, 4 and 6) Day 22 next cycle (Day 1 of next Cycle) Cycle 2 (for patients who will have interval cytoreductive surgery) Day What you do Day 1 Pre-chemotherapy medications by IV or mouth to prevent allergic reactions Go to your doctor’s office or infusion center for treatment. Receive paclitaxel and carboplatin into your vein. You will be there for approximately 2 hours. If you are receiving bevacizumab: pressure measurement Receive bevacizumab into your vein over 30-90 minutes Day 8 Get routine tests. If you are in Regimen II, receive IV paclitaxel over 1 hour. If you are receiving bevacizumab: Blood pressure measurement Between Days 8 and 10 Get your kidney health checked if it has not been done recently (10/22/2012) Get a perfusion CT scan (Cycle 2) Day 15 Get routine blood tests. If you are in Regimen II, receive IV paclitaxel over 1 hour. If you are receiving bevacizumab: Blood pressure measurement Between Days 18 and 21 History and physical examination Routine blood tests. Routine urine test Day 22 Begin next cycle (Day 1 of next Cycle) Cycles 3 and 4 (for patients who will have interval cytoreductive surgery) Day What you do Day 1 Pre-chemotherapy medications by IV or mouth to prevent allergic reactions Go to your doctor’s office or infusion center for treatment. Receive paclitaxel and carboplatin into your vein. You will be there for approximately 2 hours. Examination of incision if partially open since abdominal surgery (cycle 4) Day 8 Get routine blood tests. (for primary surgery patients only) Examination of incision if partially open since abdominal surgery (cycle 4) If you are in Regimen II, receive IV paclitaxel over 1 hour. Day 15 Get routine tests. Examination of incision if still partially open since abdominal surgery (cycle 4) If you are in Regimen II, receive IV paclitaxel over 1 hour. Between Days 15 and 21 CT or MRI scan (Cycle 3 and Cycle 6) Have interval cytoreductive surgery (cycle 3)
InformedConsent_GOG-0262_ACRIN-6695_v09.26.2012-EFF10.22.2012.docx